Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

45.33
-0.2800-0.61%
Pre-market: 45.470.1370+0.30%06:18 EDT
Volume:7.61M
Turnover:344.95M
Market Cap:200.50B
PE:11.32
High:45.61
Open:45.28
Low:44.95
Close:45.61
52wk High:64.16
52wk Low:35.12
Shares:4.42B
Float Shares:3.19B
Volume Ratio:0.68
T/O Rate:0.24%
Dividend:1.72
Dividend Rate:3.80%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:6.16
PE(LYR):12.52

Loading ...

Novo Nordisk and Eli Lilly Vie for Dominance in Oral GLP-1 Weight-Loss Market

Deep News
·
Jun 09

Novo Nordisk A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
Jun 09

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live
·
Jun 08

Movement Alert|Novo Nordisk Falls 3.07% in Regular Trading, Competitive Pressure Intensifies as Eli Lilly Surges and Patent Cliff Looms

Market Focus
·
Jun 08

Novo Nordisk Advances DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.8%

TIPRANKS
·
Jun 08

Dow Jones Top Company Headlines at 9 AM ET: Campbell's Sales Fall on Continued Weak Demand for Snacks | Nvidia ...

Dow Jones
·
Jun 08

J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)

TIPRANKS
·
Jun 08

Novo Nordisk Stock (NVO) Drops despite Obesity Updates as Eli Lilly Takes All the Shine

TIPRANKS
·
Jun 08

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. -- Barrons.com

Dow Jones
·
Jun 08

Novo Nordisk's Weight-Loss Pill Wegovy Reaches 3 Million Prescriptions Since Launch

Deep News
·
Jun 08

Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch

Dow Jones
·
Jun 08

The Wegovy pill is still dominating the GLP-1 pill market

Dow Jones
·
Jun 08

Novo Nordisk announces Reimagine 1-3 trials each met primary endpoint

TIPRANKS
·
Jun 08

Novo Nordisk announces new evidence in adults with T2D treated with semaglutide

TIPRANKS
·
Jun 08

Novo Nordisk to present new data on Wegovy across cardiometabolic conditions

TIPRANKS
·
Jun 08

Your Weight-Loss Drugs Are Next on the Corporate Chopping Block -- WSJ

Dow Jones
·
Jun 07

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Dow Jones
·
Jun 07

BRIEF-Novo Nordisk Says People With Type 2 Diabetes Who Were Increased To Semaglutide 2 Mg Were more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide

Reuters
·
Jun 06

Novo Nordisk - Semaglutide 2 Mg Matches Tirzepatide for Hba1c <7% and Outperforms for ≥5% Weight Loss at 1 Year

THOMSON REUTERS
·
Jun 06

LIVE MARKETS-GLP-1 obesity, diabetes drug market to hit $150 billion in 2030, TD Cowen says

Reuters
·
Jun 05